US · OVID
Ovid Therapeutics Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- New York City, NY 10036
- Website
- ovidrx.com
Price · as of 2024-12-31
$2.79
Market cap 116.08M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $27.65 | +891.04% |
| Intrinsic Value(DCF) | $0.21 | -92.47% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $8.49 | ||||
| 2018 | $1.94 | ||||
| 2019 | $3.16 | ||||
| 2020 | $4.10 | ||||
| 2021 | $3.38 | $287.97 | $2.95 | $11.77 | $2,716.43 |
| 2022 | $2.00 | $45.23 | $0.93 | $0.00 | $66.73 |
| 2023 | $3.08 | $31.12 | $0.31 | $0.00 | $46.46 |
| 2024 | $0.52 | $27.65 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Ovid Therapeutics Inc.'s (OVID) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $27.65
- Current price
- $2.79
- AI upside
- +891.04%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.21
-92.47% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| OVID | Ovid Therapeutics Inc. | $2.79 | 116.08M | +891% | -92% | — | — | -1.39 | 0.54 | 65.14 | 0.03 | — | 0.54 | 100.00% | -10933.75% | -4670.14% | -33.88% | -444.08% | -22.38% | 0.22 | — | 5.32 | 5.04 | 0.20 | -5000.00% | 4439.00% | 2201.00% | -151.96% | -5.32 | -402.05% | 0.00% | 0.00% | 1.37% | 0.02 | 0.03 | -2.56 | -5.32 |
| CLNN | Clene Inc. | $5.23 | 48.62M | +633% | -65% | — | +3,976% | -0.81 | -3.60 | 93.13 | -1.20 | — | -3.60 | 79.53% | -9676.32% | -11520.47% | -1738.36% | -637.51% | -98.90% | -2.35 | -8.14 | 1.57 | 1.22 | -0.26 | -3987.00% | -4771.00% | -3003.00% | -67.00% | -2.07 | -411.12% | 0.00% | 0.00% | 0.00% | -1.22 | -1.90 | 118.53 | -17.65 |
| CNTB | Connect Biopharma Holding… | $2.47 | 138.08M | — | — | — | — | -3.00 | 0.51 | 1.80 | 2.14 | — | 0.51 | 100.00% | -86.24% | -60.03% | -16.18% | 242.61% | -13.76% | 0.00 | — | 11.46 | 11.20 | 3.58 | -7407.00% | — | -4948.00% | -51.91% | -2.79 | 263.24% | 0.00% | 0.00% | 0.00% | 2.08 | 1.91 | -1.79 | -1.11 |
| CNTX | Context Therapeutics Inc. | $2.25 | 206.73M | — | — | — | — | -1.75 | 0.49 | — | 1.59 | — | 0.49 | 0.00% | — | — | -49.89% | 3929.63% | -46.81% | 0.00 | — | 35.62 | 34.36 | 3.15 | -6933.00% | — | 3927.00% | -62.65% | -5.30 | 3849.40% | 0.00% | 0.00% | 170.46% | 1.58 | 1.62 | — | 8.62 |
| IFRX | InflaRx N.V. | $0.92 | 62.33M | +5,018% | -48% | — | — | -1.32 | 0.99 | 367.43 | -0.95 | — | 0.99 | -1900.76% | -31973.69% | -27784.96% | -56.18% | -78.66% | -46.95% | 0.01 | -2566.39 | 5.06 | 1.30 | 0.39 | 0.00% | 16279.00% | 2826.00% | -79.79% | -3.43 | -72.12% | 0.00% | 0.00% | 9.72% | -0.82 | -0.89 | 261.45 | -5.01 |
| IMA | ImageneBio Inc | $6.72 | 75.14M | +440% | +18% | — | +475% | -16.94 | 6.62 | 238.26 | -20.21 | — | 6.62 | 100.00% | -1057.14% | -1044.80% | -33.30% | -524.86% | -29.52% | 0.06 | — | 11.80 | 11.54 | 0.90 | -3742.00% | -6179.00% | -4261.00% | -5.52% | -4.27 | -652.59% | 0.00% | 0.00% | 0.00% | -19.38 | -15.59 | 204.87 | 28.99 |
| KLRS | Kalaris Therapeutics Inc | $10.46 | 195.63M | — | — | — | — | -0.84 | 0.44 | — | 1.17 | — | 0.44 | 0.00% | — | — | -172.12% | 207.85% | -96.44% | 0.00 | — | 22.63 | 22.58 | 2.01 | -7213.00% | — | 37909.00% | -136.96% | -12.92 | 254.68% | 0.00% | 0.00% | 232.88% | 1.25 | 1.02 | — | -3.17 |
| MGNX | MacroGenics, Inc. | $1.99 | 125.88M | +1,648% | -54% | — | — | -2.12 | 1.22 | 0.96 | 0.38 | -0.35 | 1.22 | 91.71% | -74.54% | -45.14% | -49.85% | 242.04% | -23.91% | 0.32 | -99.17 | 3.92 | 3.71 | 2.53 | 61333.00% | 15937.00% | -987.00% | -50.71% | -1.23 | 157.77% | 0.00% | 0.00% | 55.15% | 0.20 | 0.31 | -0.15 | -5.76 |
| ORMP | Oramed Pharmaceuticals In… | $3.42 | 136.08M | +1,195% | — | — | — | -5.13 | 0.67 | — | 2.94 | — | 0.67 | 0.00% | — | — | -12.29% | -43.99% | -10.14% | 0.00 | -14.98 | 25.19 | 24.97 | 3.63 | -43571.00% | -10000.00% | -2009.00% | -8.62% | -1.48 | -29.02% | 0.00% | 0.00% | 101.31% | 3.42 | 5.19 | — | 5.11 |
| STTK | Shattuck Labs, Inc. | $3.92 | 187.78M | +1,035% | -87% | — | — | -0.83 | 0.78 | 10.91 | 0.09 | — | 0.78 | 100.00% | -1408.27% | -1318.13% | -67.23% | -568.84% | -60.18% | 0.04 | — | 8.88 | 8.19 | 0.70 | -2732.00% | 24526.00% | -2580.00% | -97.02% | -6.79 | -427.68% | 0.00% | 0.00% | 0.00% | 0.09 | 0.12 | -1.25 | -4.52 |
| WHWK | Whitehawk Therapeutics In… | $3.51 | 165.42M | +472% | -63% | — | — | -0.90 | 1.09 | 2.21 | -0.17 | — | 1.09 | -108.04% | -259.62% | -245.13% | -80.79% | -3655.27% | -62.83% | 0.02 | -438.04 | 3.59 | 3.11 | 0.43 | -328.00% | 669.00% | -382.00% | -106.81% | -3.49 | -3316.39% | 0.00% | 0.00% | 0.00% | -0.16 | -0.18 | 0.42 | -6.74 |
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
- CEO
- Margaret Alexander
- Employees
- 23
- Beta
- 0.26
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.21 ÷ $2.79) − 1 = -92.47% (DCF, example).